Literature DB >> 13678571

Necrotizing Soft Tissue Infections.

Thomas M. File1.   

Abstract

Necrotizing soft tissue infections are characterized by necrosis of skin and associated structures. Despite advances in the diagnosis and treatment of these infections, the mortality remains high. There have been increasing reports of necrotizing fasciitis caused by group A Streptococcus over the past decade. Recent information supports the role of superantigens in the pathogenesis of this infection. The approach to management requires expeditious evaluation with early surgery and appropriate antimicrobial agents. Limited data suggest that surgical debridement may be delayed in selected patients until the patient is stable by the use of intravenous immunoglobulin, which can neutralize superantigens.

Entities:  

Year:  2003        PMID: 13678571     DOI: 10.1007/s11908-003-0021-y

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  49 in total

1.  Necrotizing fasciitis: a case of clostridial myonecrosis.

Authors:  L M Kramer; L V Doering
Journal:  Am J Crit Care       Date:  2001-05       Impact factor: 2.228

2.  Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.

Authors:  R Kaul; A McGeer; A Norrby-Teglund; M Kotb; B Schwartz; K O'Rourke; J Talbot; D E Low
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

3.  Effects of diclofenac on experimental streptococcal necrotizing fasciitis (NF) in rabbit.

Authors:  F Guibal; M Muffat-Joly; B Terris; L Garry; P Morel; C Carbon
Journal:  Arch Dermatol Res       Date:  1998-11       Impact factor: 3.017

4.  Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome?

Authors:  D L Stevens
Journal:  Clin Infect Dis       Date:  1995-10       Impact factor: 9.079

5.  Necrotizing fasciitis and nonsteroidal anti-inflammatory drugs.

Authors:  R J Smith; S L Berk
Journal:  South Med J       Date:  1991-06       Impact factor: 0.954

6.  Another cause of necrotizing fasciitis?

Authors:  F Schreuder; M Chatoo
Journal:  J Infect       Date:  1997-09       Impact factor: 6.072

7.  Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection.

Authors:  J Zimbelman; A Palmer; J Todd
Journal:  Pediatr Infect Dis J       Date:  1999-12       Impact factor: 2.129

8.  Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers.

Authors:  J R DiPersio; T M File; D L Stevens; W G Gardner; G Petropoulos; K Dinsa
Journal:  Clin Infect Dis       Date:  1996-03       Impact factor: 9.079

9.  Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.

Authors:  A Norrby-Teglund; R Kaul; D E Low; A McGeer; D W Newton; J Andersson; U Andersson; M Kotb
Journal:  J Immunol       Date:  1996-04-15       Impact factor: 5.422

10.  The Treatment of Severe Group A Streptococcal Infections.

Authors:  Anna Norrby-Teglund; S. Ragnar Norrby; Donald E. Low
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

View more
  3 in total

Review 1.  Rectal cancer and Fournier's gangrene - current knowledge and therapeutic options.

Authors:  Tomislav Bruketa; Matea Majerovic; Goran Augustin
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

2.  Molecular epidemiologic comparison of 2 unusual clusters of group a streptococcal necrotizing fasciitis in Hawaii.

Authors:  Guliz Erdem; Jacqueline M Ford; Rebecca Y Kanenaka; Lucienne Abe; Karen Yamaga; Paul V Effler
Journal:  Clin Infect Dis       Date:  2005-05-09       Impact factor: 9.079

Review 3.  [Hyperbaric oxygenation for necrotizing soft tissue infections: pro].

Authors:  M Schmale; A Fichtner; C Pohl; E John; M Bucher
Journal:  Chirurg       Date:  2012-11       Impact factor: 0.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.